Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing-Reference-Cited by-同舟云学术

Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing

Published:2022-02-25 Issue:10 Volume:18 Page:1969-1979
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Ketchum Fred B.¹^ORCID,Chin Nathaniel A.²³,Grill Joshua⁴⁵,Gleason Carey E.²³⁶,Erickson Claire³⁷,Clark Lindsay R.²,Paulsen Jane S.¹,Kind Amy J.H.²³⁸

Affiliation:

1. Department of Neurology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

2. Division of Geriatrics Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

3. Wisconsin Alzheimer's Disease Research Center Madison Wisconsin USA

4. Institute for Memory Impairments and Neurological Disorders University of California, Irvine Irvine California USA

5. Departments of Psychiatry and Human Behavior and Neurobiology and Behavior University of California, Irvine Irvine California USA

6. Geriatric Research Education and Clinical Center (11G) William S. Middleton Memorial Veterans Hospital Madison Wisconsin USA

7. Neuroscience & Public Policy Program University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

8. Center for Health Disparities Research University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

Funder

National Institute on Aging

National Institutes of Health

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12620

Reference84 articles.

1. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals

2. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

3. Disclosure of individual research results at federally funded Alzheimer's Disease Research Centers

4. From information to follow‐up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting

5. Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reasons for undergoing amyloid imaging among diverse enrollees in the A4 study;Alzheimer's & Dementia;2024-07-23

2. Concerns with the new biological research criteria for synucleinopathy – Authors' reply;The Lancet Neurology;2024-07

3. Diagnosing Preclinical and Prodromal Neurodegenerative Diseases—The Clinical Is Political;JAMA Neurology;2024-05-01

4. Associations of Everyday and Lifetime Experiences of Discrimination With Willingness to Undergo Alzheimer Disease Predictive Testing;Neurology;2024-02-27

5. Informing Alzheimer’s Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure;The Journal of Prevention of Alzheimer's Disease;2024